Here's Why Investors Should Retain Athenahealth (ATHN) Stock
Zacks Investment Research | Jan 16, 2019 09:30PM ET
athenahealth, Inc.’s (NASDAQ:ATHN) strong product portfolio, solid network expansion strategies and unique business model buoy optimism. However, the company faces cutthroat competition in the MedTech space.
In the past year, shares of this Zacks Rank #3 (Hold) company have lost 3.2%, outperforming its industry 's 18.5% decline. The current level also compares favorably with the S&P 500 index's 7.6% decline.
Here we take a quick look at the primary factors that have been plaguing athenahealth and discuss the prospects that ensure its near-term recovery.
Cutthroat Market Competition
athenahealth’s EHR solution faces stiff competition from the likes of Allscripts Healthcare Solutions and others. MedTech behemoths like Cerner offer long-standing seamless products integrating inpatient and ambulatory-care systems.
Further, SaaS-based models put athenahealth’s pricing under pressure. Stringent hospital budgets also lead to weak pricing, which will continue to hurt athenahealth’s profitability.
Why Should You Hold the Stock?
athenahealth’s portfolio comprises a wide array of products that include electronic health records, revenue cycle management, medical billing, patient engagement, care coordination, population health management and Epocrates.
athenaInsight, an online news hub that reports on U.S. healthcare activities and trends of healthcare providers and ‘de-identified patients’, has also been fortifying the company’s footprint.
Last year, athenahealth rapidly expanded its patient record sharing capabilities with CommonWell and Carequality.
Notably, athenaClinicals is the company’s first economically sustainable, service-based electronic medical records (EMR) system. Among other activities, athenahealth purchased Proxsys, LLC — a care coordination company — and launched athenaCoordinator (now athenaCoordinator Core) for order transmission and care collaboration with secure text message.
These apart, athenahealth recently announced that it has entered into a definitive agreement under which to be acquired by Veritas Capital for approximately $5.7 billion in cash. Under the terms of the deal, athenahealth shareholders will receive $135 in cash per share. After the completion of the acquisition, athenahealth is expected to be combined with Virence Health ("Virence") – the GE Healthcare Value-based Care assets – that Veritas acquired earlier this year. The transaction is expected to close in the first quarter of 2019.
Which Way Are Estimates Headed?
For the fourth quarter of 2019, the Zacks Consensus Estimate for earnings is pegged at $1.14, up 2.7% year over year. The same for revenues is pinned at $358.3 million, mirroring an increase of 8.9% year over year.
For 2019, the Zacks Consensus Estimate for revenues is $1.35 billion. The same for earnings stands at $4.20, up 69.4% year over year.
Get The News You Want
athenahealth, Inc. Price and Consensus
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.